TITLE

piroxicam

AUTHOR(S)
Peters, Michael
PUB. DATE
June 2004
SOURCE
BMA A-Z Family Medical Encyclopedia;2004, p609
SOURCE TYPE
Book
DOC. TYPE
Reference Entry
ABSTRACT
An encyclopedia entry for "piroxicam" is presented. It is a type of nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of types of arthritis and to relieve pain in bursitis, tendinitis and after minor surgery. Adverse side effects may include nausea, indigestion, abdominal pain, swollen ankles, peptic ulcer and liver problems.
ACCESSION #
44000073

 

Related Articles

  • Less than half of patients with GI risk factors on NSAIDs receive GI prophylaxes. Brockenbrough, Gina // Orthopedics Today;Jul2008, Vol. 28 Issue 7, p63 

    The article reports on the low prescription rate of nonsteroidal anti-inflammatory agents (NSAIDs) with gastrointestinal (GI) prophylaxis in patients with arthritis and GI risk factors based on a study conducted by orthopedist Khaled J. Saleh and colleagues in the U.S. They found that 12.1% of...

  • Selective transport of copper(II) ions across a liquid membrane mediated by Piroxicam. Sadeghi, Susan; Mohammadzadeh, Darush; Imampur, Jalal Shakhs // Analytical & Bioanalytical Chemistry;Sep2005, Vol. 383 Issue 2, p261 

    Piroxicam was found to be a highly selective carrier for uphill transport of Cu2+ ions through a chloroform liquid membrane. The transport occurs via a counterflow of protons from the receiving phase to the source phase. The effects of several parameters on the transport of Cu2+ ions, such as...

  • The cyclo-oxygenase inhibitor, Piroxicam, enhances cytokine-induced lymphocyte proliferation in vitro and in vivo. Haynes, D. R.; Wright, P. F.; Whitehouse, M. W.; Vernon-Roberts, B. // Immunology & Cell Biology;Aug1990, Vol. 68 Issue 4, p225 

    The effects of Piroxicam on the production and activity of lymphoproliferative cytokines (LC) produced by mononuclear phagocytes (MNP) were examined. In vitro, Piroxicam did not affect IL-1 induced thymocyte proliferation (LAF assay). However, the LAF activity from lipopolysaccharide...

  • Design and Characterization of Fast Disintegrating Tablets of Piroxicam. Modasiya, M. K.; Lala, I. I.; Prajapati, B. G.; Patel, V. M.; Shah, D. A. // International Journal of PharmTech Research;Apr2009, Vol. 1 Issue 2, p353 

    Piroxicam is an effective and selective cyclo-oxygenase COX-2 inhibitor with anti - inflammatory and analgesic properties. The poor aqueous solubility of the drug leads to variable dissolution rates. In the present study an attempt has been made to prepare fast disintegrating tablets of...

  • Piroxicam.  // Reactions Weekly;3/12/2005, Issue 1042, p17 

    Discusses research being done on two women who developed fixed drug eruptions during treatment with piroxicam. Reference to a study by E. C. Galindo, J. M. G. Silva, M. V. Hernando, et al., published in the September 2004 issue of the "Journal of the European Academy of Dermatology and...

  • Spectrofluorimetric Determination of Piroxicam in Pharmaceutical Preparations and Spiked Human Serum Using Micellar Media. Manzoori, Jamshid L.; Amjadi, Mohammad // Microchimica Acta;Sep2003, Vol. 143 Issue 1, p39 

    The fluorescence properties of piroxicam in various micellar media were investigated. It was found that the presence of 0.05 M sodium dodecyl sulfate (SDS) surfactant (pH 1.5–2, nitric acid) causes an approximately 5-fold enhancement in the fluorescence of this drug. An experimental...

  • EMEA recommends restrictions for piroxicam use.  // Reactions Weekly;6/30/2007, Issue 1158, p2 

    The article reports that the European Medicines Agency has recommended restrictions on piroxicam-containing products due to a risk of GI adverse effects and serious skin reactions. The agency's Committee for Medicinal Products for Human Use has suggested new contraindications and has...

  • Piroxicam.  // Reactions Weekly;3/11/2006, Issue 1092, p21 

    Discusses research on Nicolau syndrome following intra-articular injection of piroxicam in a 66-year-old woman. Reference to a study by D. P. Lee, G. Y. Bae et al published in the December 2005 issue of "International Journal of Dermatology"; Signs and symptoms manifested by the woman;...

  • Toxico-Neurological Effects of Piroxicam in Monogastric Animals. Saganuwan, Saganuwan Alhaji; Orinya, Orinya Agbaji // Journal of Experimental Neuroscience;2016, Issue 10, p121 

    Piroxicam is a benzothiazine compound with anti-inflammatory, antipyretic, and analgesic properties. Because of the very high efficacy of piroxicam and its increasing use in the treatment of carcinomas in dogs and cats, there is a need for acute toxicity study of piroxicam in monogastric animals...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics